“Less Harmful Coalition Summit”: Dr. Renée O’Leary analyze EU and Canadian policy narratives

Post author:Chiara Nobis
Post published:14 November 2022
Post category:Press Release

"Policy narratives are socially constructed stories produced within belief systems that narrate the reality of the policy problem and assign blame. The purpose of policy narratives is persuasion, to influence the framing of a policy problem and shape policy beliefs - said dr. O'Leary - So long as the narratives in the state arena about vapour devices are only stories of threats, any potential opportunity vapour devices may offer for tobacco harm reduction is automatically lost".

Risk reduction in Italy: Rome 9th November

Post author:Chiara Nobis
Post published:7 November 2022
Post category:Press Release

"Risk reduction as a public health strategy to eradicate cigarette smoking", is going to be discussed in Rome on Wednesday 9th November as part of a conference promoted by Motor Health in the "Sala Cristallo" of Hotel Nazionale in Piazza Montecitorio.

COPD and smoking: Polosa attends the Congress “Le strade del Respiro”

Post author:Chiara Nobis
Post published:4 November 2022
Post category:Press Release

prof. Riccardo Polosa, founder of the CoEHAR and one of the leading experts in the field of harm reduction strategies, will speak at the first edition of the congress "Le strade del Respiro", which will be held on Saturday 5 November in Rome.

CNBC Dubai: Prof. Polosa speaker on Harm Reduction

Post author:Chiara Nobis
Post published:31 October 2022
Post category:Press Release

Among the distinguished speakers, also the expected speech by prof. Riccardo Polosa, founder of CoEHAR.

Riccardo Polosa at the National Congress of the Italian Society of Internal Medicine

Post author:Chiara Nobis
Post published:27 October 2022
Post category:Press Release

Harm Reduction strategies were the subject of a speech by prof. Polosa during the National Congress of the Italian Society of Internal Medicine. Focus of this year edition, the management of…

Washington, GTNF 2022: Polosa attending a panel on vaping prohibition

Post author:Chiara Nobis
Post published:4 October 2022
Post category:Press Release

During the 2022 edition of GTNF, the Global Tobacco and Nicotine Forum, Prof. Riccardo Polosa, founder of the CoEHAR, was part of an intense and engaging panel on vaping and tobacco policies at the panel “Banned! Is Prohibition Back?”.

Replica Project at the Scientific Summit on Tobacco Harm Reduction

Post author:Chiara Nobis
Post published:5 September 2022
Post category:Replica

The 5th Scientific Summit on Tobacco Harm Reduction: Novel products, Research & Policy, is organised by SCOHRE, the International Association on Smoking Control & Harm Reduction, and will be held on…

Polosa and Goniewicz the world’s most influential e-cigarette researchers, a new bibliometrics analysis concludes

Post author:Chiara Nobis
Post published:8 August 2022
Post category:Press Release

The mapping of Global Research on electronic cigarettes showed that prof. Riccardo Polosa (CoEHAR Center of Excellence for the Acceleration of HArm Reduction, University of Catania) and prof. Maciej L. Goniewicz (Roswell Park Comprehensive Cancer Center, USA) are the most influential authors and the most important researchers in the e-cigarettes research field.

Evidence for Clinicians: E-Cigarettes a Better Chance at Health

Post author:Chiara Nobis
Post published:12 July 2022
Post category:In Silico Press Release

The In Silico Science research team conducted a series of robust and exhaustive systematic reviews to bring forward the best available evidence on the health effects of e-cigarettes on human health developing data for clinicians

US: end of teen nicotine vaping epidemic and eradication of tobacco smoking

Post author:Chiara Nobis
Post published:23 June 2022
Post category:Press Release

The use of e-cigarette among teenagers in the United States is considered a significant public health problem. A close look at federal data now show that the number of young e-cigarette users has markedly declined to below epidemic levels since its peak in 2019.